Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Goel R, Cushing MM, Tobian AA. Pediatric Patient Blood Management Programs: Not Just Transfusing Little Adults. Transfus Med Rev. 2016;30(4):235-41.

Avecilla ST, Goss C, Bleau S, Tonon J-, Meagher RC. How do I perform hematopoietic progenitor cell selection? Transfusion. 2016;56(5):1008-12.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, et al. Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Res Treat. 2016;156(2):405-6.

Cushing MM, Asmis L, Calabia C, Rand JH, Haas T. Efficacy of solvent/detergent plasma after storage at 2-8 °C for 5 days in comparison to other plasma products to improve factor V levels in factor V deficient plasma. Transfus Apher Sci. 2016;55(1):114-9.

Trasino SE, Tang X-, Jessurun J, Gudas LJ. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease. J Mol Med (Berl). 2016;94(10):1143-1151.

Carden MA, Caltharp S, Yee ME, Haight AE, Westblade LF, Park S. Recipient-derived EBV-positive Monomorphic Plasmacytoma Type Posttransplant Lymphoproliferative Disorder After Allogeneic Stem Cell Transplant for Severe Aplastic Anemia: A Case Report. J Pediatr Hematol Oncol. 2016;38(8):e310-e314.

Santo EE, Paik J. FOXO3a & haematopoietic stem cells: Goodbye PI3K, hello SIRT1? Cell Cycle. 2016;15(7):879-80.

Evans JR, Zhao SG, S Chang L, Tomlins SA, Erho N, Sboner A, et al. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016;2(4):471-80.

Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559-63.

Wang D, Narula N, Azzopardi S, Smith RS, Nasar A, Altorki NK, et al. Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. Oncotarget. 2016;7(26):39957-39969.